Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00413699 · ClinicalTrials.gov registry record · Phase 3
Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 4,488
- Enrollment target
NCT00413699 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 4,488 participants.
The verdict
NCT00413699, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 4,488 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the long-term effectiveness and safety of CP-690,550 for the treatment of rheumatoid arthritis. Subjects are eligible for this study only after participating in another "qualifying" study of CP-690,550 A sub-study will be conducted within the A3921024 study, this study will evaluate the immune response to pneumococcal and influenza vaccines in patients receiving CP-690,550
Interventions
- DRUG CP-690,550
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,488 participants |
| Start Date | 2007-02-05 |
| Est. Completion | 2017-10-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00413699
The ClinicalTrials.gov registry entry for NCT00413699 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 4,488 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CP-690,550 is the first listed.
NCT00413699 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00413699 about?
NCT00413699 is a clinical study titled "Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis". The purpose of this study is to determine the long-term effectiveness and safety of CP-690,550 for the treatment of rheumatoid arthritis. Subjects are eligible for this study only after participating in another "qualifying" study of CP-690,550 A sub-study will be conducted within the A3921024 study...
What is the current status of trial NCT00413699?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 4,488 participants. The study started on 2007-02-05. Estimated completion is 2017-10-26.
What interventions are being tested in trial NCT00413699?
The interventions under investigation include: CP-690,550 (DRUG).
Who is sponsoring clinical trial NCT00413699?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.